# US 2003/0224381 A1 · Delta-erythroid kruppel-like factors and methods of use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0224381 A1
- Document ID: US20030224381A1
- Status: Published application
- Kind: A1
- Application number: 10/289,152
- Filed: 2002-11-05
- Published: 2003-12-04
- Earliest claimed: 1996-06-14
- Inventors: Tim M. Townes; David Donze
- Web page: https://patentgrep.com/patent/US20030224381A1

## CPC

- A61K 31/711: Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
- C07K 14/4702: {Regulators; Modulating activity}
- C07K 14/805: Haemoglobins; Myoglobins
- C12N 15/85: for animal cells
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C12N 2799/025: where the vector is derived from a parvovirus
- C12N 2800/108: episomal vectors
- C12N 2830/00: Vector systems having a special element relevant for transcription
- C12N 2830/008: cell type or tissue specific enhancer/promoter combination
- C12N 2830/15: chimeric enhancer/promoter combination
- C12N 2830/85: mammalian
- C12N 2840/20: translation of more than one cistron
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The invention features δ-erythroid krüppel-like factors (δ-EKLFs), and methods of using nucleic acids encoding δ-EKLFs to increase δ-globin gene expression in a cell.

## Claims

### Claim 1

A method of inducing δ-globin gene expression in a cell, said method comprising introducing a nucleic acid encoding a δ-EKLF polypeptide into said cell or into a precursor of said cell.

### Claim 2 (depends on 1)

The method of claim 1, wherein said cell is a pluripotent, hematopoietic stem cell.

### Claim 3 (depends on 1)

The method of claim 1, wherein said cell is an erythrocyte precursor cell.

### Claim 4 (depends on 3)

The method of claim 3, wherein said erythrocyte precursor cell is an erythrocyte burst-forming cell (BFC-E) or an erythrocyte colony-forming cell (CFC-E).

### Claim 5 (depends on 1)

The method of claim 1, wherein said cell is an erythrocyte.

### Claim 6 (depends on 1)

The method of claim 1, wherein said cell is present in a mammal.

### Claim 7 (depends on 1)

The method of claim 1, wherein said cell, or a precursor of said cell, has been removed from a mammal.

### Claim 8 (depends on 7)

The method of claim 7, wherein said cell is a hematopoietic stem cell.

### Claim 9 (depends on 7)

The method of claim 7, wherein said mammal has a hemoglobinopathy.

### Claim 10 (depends on 9)

The method of claim 9, wherein said hemoglobinopathy is selected from the group consisting of sickle cell anemia and P′-thalassemia.

### Claim 11

A δ-EKLF polypeptide.

### Claim 12

A nucleic acid encoding a δ-EKLF polypeptide.

### Claim 13

A cell that contains a nucleic acid encoding a δ-EKLF polypeptide.

### Claim 14 (depends on 13)

The cell of claim 13, wherein said cell is a hematopoietic stem cell.

### Claim 15 (depends on 13)

The cell of claim 13, wherein said cell is an erythrocyte precursor cell.

### Claim 16

A vector containing a nucleic acid encoding a δ-EKLF polypeptide.

### Claim 17 (depends on 16)

The vector of claim 16, wherein said vector is an adeno-associated viral (AAV) vector.

### Claim 18 (depends on 16)

The vector of claim 16, wherein said vector is a retroviral vector.

### Claim 19

A method for identifying a δ-EKLF polypeptide, said method comprising contacting a nucleic acid containing the sequence 5′-TGA AAC CCT-3′ or the sequence 5′-CTA ATG AAA-3′ with a candidate polypeptide that has been modified such that it differs from wild type β-EKLF by at least one amino acid and identifying said polypeptide by its ability to bind to said nucleic acid.

### Claim 20 (depends on 19)

The method of claim 19, wherein said amino acid is in a β-EKLF zinc finger that binds DNA.
